Oruka Therapeutics (ORKA) vs Achieve Life Sciences (QUIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oruka Therapeutics is the larger company by market cap ($6.50 billion vs $573.2 million), about 11.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORKA | QUIT |
|---|---|---|
| Share price | $95.81 | $5.56 |
| Market cap | $6.50B | $573.25M |
| 1-day change | -1.80% | -5.28% |
| YTD return | +216.10% | — |
| 1-year return | +227.11% | — |
| 5-year return | +205.91% | — |
| EPS (TTM) | $-2.12 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-105.43M | $-54.65M |
| 52-week high | $115.52 | $8.64 |
| 52-week low | $25.23 | $2.62 |
| Distance from 52-week high | -17.06% | -35.65% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.00% | +162.23% |
| Average volume | 965.27K | 1.38M |
| Shares outstanding | 67.82M | 103.10M |
| Employees | 68 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 11.3 times larger than Achieve Life Sciences by market value ($6.50B vs $573.25M).
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
ORKA vs QUIT FAQ
Which is bigger, Oruka Therapeutics or Achieve Life Sciences?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $6.50B compared with $573.25M for Achieve Life Sciences (QUIT).
Are Oruka Therapeutics and Achieve Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.